- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Mo | CARsgen Therapeutics: CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B | 65 | PR Newswire | SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 21.10. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 20.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS OF SATRI-CEL AT THE ESMO CONGRESS 2025 | 2 | HKEx | ||
| 08.10. | CARsgen Therapeutics: CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology | 50 | PR Newswire | SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 06.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT UPDATED RESEARCH RESULTS OF CT0596 AT ASH 2025 ANNUAL CONGRESS | 1 | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.09. | CARSGEN-B (02171): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.09. | CARSGEN-B (02171): PASSING AWAY OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 18.09. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME | 2 | HKEx | ||
| 18.09. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL AT 22ND IMS ANNUAL MEETING OF 2025 | - | HKEx | ||
| 04.09. | CARSGEN-B (02171): INTERIM REPORT 2025 | 1 | HKEx | ||
| 04.09. | CARSGEN-B (02171): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | - | HKEx | ||
| 15.08. | CARsgen Therapeutics Holdings reports H1 results | 3 | Seeking Alpha | ||
| 15.08. | CARsgen Therapeutics Announces 2025 Interim Results | 471 | PR Newswire | SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 14.08. | CARSGEN-B (02171): ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT ... | 2 | HKEx | ||
| 01.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 25.07. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 1 | HKEx | ||
| 22.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL FOR ADJUVANT THERAPY OF PANCREATIC CANCER ACCEPTED FOR POSTER PRESENTATION ... | 2 | HKEx | ||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL ... | 2 | HKEx | ||
| 16.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON CT071 AT 2025 EHA ANNUAL CONGRESS | 3 | HKEx |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,355 | -2,26 % | Qiagen plant CEO-Wechsel und will 500 Millionen Dollar an Aktionäre auszahlen | Qiagen plant, über einen synthetischen Aktienrückkauf bis zu 500 Millionen US-Dollar an seine Aktionäre zurückzuzahlen. Das gestern Abend angekündigte Programm kombiniert eine Kapitalrückzahlung mit... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,150 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 18,205 | -12,89 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,78 | -0,03 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| NUVALENT | 95,87 | +4,21 % | Nuvalent to present zidesamtinib patient data at lung cancer conference | ||
| EVOTEC | 5,818 | 0,00 % | Evotec: Aktie auf Achterbahnfahrt nach Sandoz-Deal und Zahlen | Evotec hat in den ersten neun Monaten 2025 einen Umsatzrückgang von 7,1 Prozent auf 535 Millionen Euro verzeichnet, nach 576 Millionen Euro im Vorjahreszeitraum. Das bereinigte Konzern-EBITDA lag mit... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,030 | 0,00 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| MODERNA | 20,575 | -0,10 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 12,460 | -5,75 % | Amylyx targets avexitide launch in 2027 with recruitment completion for LUCIDITY now expected in Q1 2026 | ||
| RECURSION PHARMACEUTICALS | 4,605 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| BIONTECH | 88,95 | -0,61 % | BioNTech: Die Zahlen sind da - Prognose erhöht | BioNTech hat im dritten Quartal 2025 einen Umsatz von 1,52 Milliarden Euro erzielt, nach 1,24 Milliarden Euro im Vorjahreszeitraum. Der Anstieg ist vor allem auf Zahlungen aus der Kooperation mit Bristol... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,140 | +3,16 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,991 | -0,01 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,920 | 0,00 % | Taysha Gene Therapies: Citizens hebt Kursziel auf 8 US-Dollar an | ||
| MONTE ROSA THERAPEUTICS | 13,010 | 0,00 % | Monte Rosa Therapeutics reports Q3 results |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.